CoChat

Cerebrolysin for vascular dementia

Open access
Chen, Ning, Yang, Mi, Guo, Jian, Zhou, Muke, Zhu, Cairong, He, Li · 2013 · Cochrane Database of Systematic Reviews
Cited by 90

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Although vascular dementia is the second most common cause of dementia globally, evidence-based treatments are still lacking. Cerebrolysin is a porcine brain-derived preparation that is said to have neurotrophic and neuroprotective activity. In many parts of the world Cerebrolysin, given as a series of daily intravenous infusions, is used as a potential intervention for vascular dementia. A previous Cochrane Review on Cerebrolysin in vascular dementia yielded inconsistent results. We wished to update the review to add new studies from the international literature and employ contemporary methods for appraising the strength of the evidence. This is the first update of a review first published in 2013. OBJECTIVES: Primary: to assess the effect of Cerebrolysin on cognitive function, global function, and all-cause mortality in people living with vascular dementia. Secondary: to assess the adverse effects of Cerebrolysin and to assess the effect of Cerebrolysin on quality of life and caregiver burden. SEARCH METHODS: We searched ALOIS, MEDLINE, Embase, PsycINFO, CINAHL, ISI Web of Knowledge, LILACS, the Cochrane Library, ClinicalTrials.gov, and the WHO ICTRP on 16 June 2017, 9 May 2018, and 9 May 2019. We expanded the search by adding four Chinese databases, searched from 1 January 2012 to 19 May 2019. We checked bibliographies of relevant papers identified and contacted pharmaceutical companies, trial authors, and experts in the field to identify any additional published or unpublished data. SELECTION CRITERIA: We included all randomised controlled trials of Cerebrolysin used in people living with vascular dementia. We applied no language restriction. DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials for inclusion and evaluated their methodological quality. Data were extracted and analysed using mean differences (MDs) or standardised mean differences (SMDs) with 95% confidence intervals (95% CI) for continuous outcomes. We reported dichotomous outcomes as risk ratio (RR) with 95% CI. We assessed the strength of the available evidence using the GRADE approach. MAIN RESULTS: We identified six randomised controlled trials with a total of 597 participants that were eligible for inclusion in the 2013 review. No new studies were eligible for inclusion in this update. Participants in the included studies, where dementia severity was reported, had mild to moderate severity of vascular dementia (four trials). The included studies tested varying doses and duration of Cerebrolysin treatment. Follow-up ranged from 15 days to three years. Five of included studies were conducted in China (three studies), Russia (one study), and Romania (one study), while relevant information of other study was unclear. Where details of funding were available, all studies were supported by the pharmaceutical industry (three studies). Cognitive function was measured using the Mini-Mental State Examination (MMSE) or Alzheimer's Disease Assessment Scale Cognitive Subpart, extended version (ADAS-cog+). Combining the MMSE and ADAS-cog+ data (three studies, 420 people), there was a beneficial effect of Cerebrolysin (SMD 0.36, 95% CI 0.13 to 0.58; very low-quality evidence). Global function was measured by Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC+) or Investigator's Clinical Global Impression (CGI). We assessed response rates on these measures (the proportion of participants with a CIBIC+ score of < 3; or at least moderate improvement of the CGI rating at the last visit). There was a beneficial effect of Cerebrolysin (two studies, 379 participants, RR 2.69, 95% CI 1.82 to 3.98; very low-quality evidence). Only one trial described mortality and reported no deaths. Four studies reported adverse events; data from two studies (379 people) were in a format that permitted meta-analysis, and there was no difference in rates of adverse effects (RR 0.91, 95% CI 0.29 to 2.85; very low-quality evidence). No studies reported on quality of life or caregiver burden. AUTHORS' CONCLUSIONS: Courses of intravenous Cerebrolysin improved cognition and general function in people living with vascular dementia, with no suggestion of adverse effects. However, these data are not definitive. Our analyses were limited by heterogeneity, and the included papers had high risk of bias. If there are benefits of Cerebrolysin, the effects may be too small to be clinically meaningful. There have been no new studies of Cerebrolysin in vascular dementia since the last Cochrane Review. Cerebrolysin continues to be used and promoted as a treatment for vascular dementia, but the supporting evidence base is weak. Adequately powered, methodologically robust trials are needed to properly assess the effects of Cerebrolysin in vascular dementia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd008900.pub2

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 74

  1. Guekht A Doppler E Moessler H Gusev E Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double-blind, placebo-controlled, multicenter trial European Journal of Neurology 2009 391
  2. Guekht, 2011, Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial, Journal of Stroke and Cerebrovascular Diseases, 20, 310, 10.1016/j.jstrokecerebrovasdis.2010.01.012 · DOI
  3. Liang, 2001, The efficacy of Cerebrolysin in multi-infarct dementia, Heilongjiang Medicine and Pharmacy, 24, 75
  4. Muresanu, 2008, A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration, Journal of the Neurological Sciences, 267, 112, 10.1016/j.jns.2007.10.016 · DOI
  5. Muresanu, 2010, Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study, Journal of the Neurological Sciences, 299, 179, 10.1016/j.jns.2010.08.040 · doi:10.1016/j.jns.2010.08.040
  6. Vereschagin, 1991, Mild forms of multi-infarct dementia - effectiveness of Cerebrolysin, Sovetskaya Meditsina, 11, 6
  7. Xiao, 1999, The efficacy of Cerebrolysin in patients with vascular dementia: Results of a Chinese multicentre, randomised, double-blind, placebo-controlled trial, Hong Kong Journal of Psychiatry, 9, 13
  8. Xiao, 1999, A multi-center, double blind, placebo-controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia, Journal of Clinical Psychological Medicine, 9, 1
  9. Zhang, 2003, Cerebrolysin improves the intelligence of vascular dementia patients in clinic, Chinese Journal of Clinical Rehabilitation, 7, 3850
  10. Cao, 2000, Application of Cerebrolysin in ischaemic cerebrovascular disease, Clinical Focus, 21, 986
  11. Chen, 2006, Efficacy of Cerebrolysin for vascular dementia, Chinese Journal of Practical Medicine, 9, 1019
  12. Dai, 2011, Efficacy of Cerebrolysin in 41 patients with vascular dementia, Chinese and Foreign Medical Research, 15, 44
  13. Damulin, 2008, Effects of Cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study), Neuroscience and Behavioral Physiology, 38, 639, 10.1007/s11055-008-9014-5 · DOI
  14. Jia, 1991, Application of Cerebrolysin in 30 patients of post stroke dementia, New Drugs and Clinical Remedies, 10, 129
  15. Li, 1996, Application of Cerebrolysin in 20 patients with vascular dementia, Anhui Medicine, 5, 41
  16. Meng, 2001, The efficacy of Cerebrolysin for 62 old patients with vascular dementia, Journal of Mudanjiang Medical College, 22, 25
  17. Pan, 1999, Efficacy of Cerebrolysin in 20 patients with vascular dementia, Herald of Medicine, 3, 147
  18. Suvorova, 2010, Neuroprotective therapy in basic treatment of vascular dementia, European Neuropsychopharmacology, 20, S561, 10.1016/S0924-977X(10)70847-6 · doi:10.1016/s0924-977x(10)70847-6
  19. Tapu, 2009, The efficacy of cerebrolysin in vascular dementia, Journal of the Neurological Sciences, 283, 286, 10.1016/j.jns.2009.02.177 · doi:10.1016/j.jns.2009.02.177
  20. Vereschagin, 2001, Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of randomised double blind placebo-controlled study of cerebrolysin, Terapevticheskii Arkhiv, 73, 22
  21. Wang, 1996, Comparative study of cytidine diphosphate choline and cerebrolysin for cerebrovascular disease and vascular dementia, New Drugs and Clinical Remedies, 15, 244
  22. Wang, 2003, Efficacy of cerebrolysin in patients with multi-infarct dementia, Proceeding of Clinical Medicine, 12, 362
  23. Xian, 2004, Effect of galanthamine on memory and quality of life in patients with vascular dementia, Chinese Journal of Clinical Rehabilitation, 8, 3022
  24. Zheng, 1999, Efficacy of cerebrolysin for vascular dementia, Heilongjiang Medicine and Pharmacy, 22, 103
  25. Aggarwal, 2007, Vascular dementia: emerging trends, Seminars in Neurology, 27, 66-77, 10.1055/s-2006-956757 · DOI
  26. Akai, 1992, Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain, Histology and Histopathology, 7, 213
  27. American Psychiatric Association, 1980, Diagnostic and statistical manual of mental disorders
  28. American Psychiatric Association, 1987, Diagnostic and statistical manual of mental disorders, 3rd edition, revised
  29. American Psychiatric Association, 1994, Diagnostic and statistical manual of mental disorders
  30. Benisty, 2008, Diagnostic criteria of vascular dementia in CADASIL, Stroke, 39, 838, 10.1161/STROKEAHA.107.490672 · DOI · Paper page
  31. Deeks, 2011, Chapter 9: Analysing data and undertaking meta-analyses
  32. Dong, 2007, The prevalence of dementia in the People's Republic of China: a systematic analysis of 1980-2004 studies, Age and Ageing, 36, 619, 10.1093/ageing/afm128 · DOI · Paper page
  33. Feigin, 2005, Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease?, Journal of the Neurological Sciences, 229-30, 151, 10.1016/j.jns.2004.11.020 · DOI
  34. Folstein, 1975, "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
  35. Fragoso, 2009, Cerebrolysin for Alzheimer's disease (Protocol), Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003801 · DOI
  36. Hao, 2009, Huperzine A for vascular dementia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD007365.pub2 · DOI
  37. Hartbauer, 2001, Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons, Journal of Neural Transmission, 108, 581, 10.1007/s007020170058 · DOI
  38. Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Statistics in Medicine, 21, 1539, 10.1002/sim.1186 · DOI · Paper page
  39. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  40. Higgins JPT Deeks JJ (editors) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
  41. Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
  42. Hong, 2005, The clinical efficacy of Cerebrolysin in the treatment of acute ischemic stroke, Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 7, 331
  43. International Conference on Harmonisation Expert Working Group International Conference on Harmonisation of technical requirements for registration of Pharmaceuticals for human use adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use International Digest of Health Legislation 1997 231 4
  44. Korczyn, 2012, Vascular dementia, Journal of the Neurological Sciences, 322, 2, 10.1016/j.jns.2012.03.027 · DOI
  45. Ladurner, 2005, Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial, Journal of Neural Transmission, 112, 415, 10.1007/s00702-004-0248-2 · DOI
  46. Masliah, 1999, Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice, Pharmacology Biochemistry and Behaviour, 62, 239, 10.1016/S0091-3057(98)00144-0 · DOI
  47. Mohs, 1997, Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study, Alzheimer Disease & Associated Disorders, 11, S13, 10.1097/00002093-199700112-00003 · DOI · Paper page
  48. Muresanu, 2008, A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration, Journal of the Neurological Sciences, 267, 112, 10.1016/j.jns.2007.10.016 · DOI
  49. Muresanu, 2010, Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study, Journal of the Neurological Sciences, 299, 179, 10.1016/j.jns.2010.08.040 · doi:10.1016/j.jns.2010.08.040
  50. Nasreddine, 2005, The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment, Journal of the American Geriatric Society, 53, 695, 10.1111/j.1532-5415.2005.53221.x · DOI · Paper page
  51. O'Brien, 2006, Vascular cognitive impairment, American Journal of Geriatric Psychiatry, 14, 724, 10.1097/01.JGP.0000231780.44684.7e · DOI
  52. Pantoni, 1993, Hachinski's ischemic score and the diagnosis of vascular dementia: A review, Italian Journal of Neurological Sciences, 14, 539, 10.1007/BF02339212 · DOI
  53. Plosker, 2009, Cerebrolysin: a review of its use in dementia, Drugs and Aging, 26, 893, 10.2165/11203320-000000000-00000 · DOI
  54. Plosker, 2010, Spotlight on cerebrolysin in dementia, CNS Drugs, 24, 263, 10.2165/11204820-000000000-00000 · DOI
  55. Rainer, 1997, Therapeutic results with Cerebrolysin in the treatment of dementia, Wiener Medizinische Wochenschrift, 147, 426
  56. Renna, 2003, Low baseline Bispectral Index of the electroencephalogram in patients with dementia, Anesthesia and Analgesia, 96, 1380, 10.1213/01.ANE.0000059223.78879.0F · DOI
  57. Rockenstein, 2003, The neuroprotective effects of Cerebrolysin TM in a transgenic model of Alzheimer's disease are associated with improved behavioral performance, Journal of Neural Transmission, 110, 1313, 10.1007/s00702-003-0025-7 · DOI
  58. Rockenstein, 2005, Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin, Journal of Neural Transmission, 112, 269, 10.1007/s00702-004-0181-4 · DOI
  59. Rockenstein, 2006, Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease, Journal of Neuroscience Research, 83, 1252, 10.1002/jnr.20818 · DOI · Paper page
  60. Román, 2002, Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention, Medical Clinics of North America, 86, 477, 10.1016/S0025-7125(02)00008-1 · DOI
  61. Satou, 1993, Morphological observation of effects of Cerebrolysin on cultured neural cells, Advances in the Biosciences, 87, 195
  62. Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
  63. Tatebayashi, 2003, The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease, Acta Neuropathologica, 105, 225, 10.1007/s00401-002-0636-3 · DOI
  64. Veinbergs, 2000, Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity, Journal of Neural Transmission Supplement, 59, 273
  65. Wei, 2007, Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease, Journal of Neural Transmission, 114, 629, 10.1007/s00702-007-0630-y · DOI
  66. World Health Organization, 1992, The 10th revision of the International Classification of Disease and relative health problems (ICD-10)
  67. Windisch, 1998, Neurotrophic activities and therapeutic experience with a brain derived peptide preparation, Journal of Neural Transmission Supplement, 53, 289, 10.1007/978-3-7091-6467-9_25 · DOI
  68. Wu, 2007, Yizhi capsule for vascular dementia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005382.pub2 · DOI
  69. Zhang, 2012, Prevalence of dementia and major dementia subtypes in the Chinese populations: A meta-analysis of dementia prevalence surveys, 1980-2010, Journal of Clinical Neuroscience, 19, 1333, 10.1016/j.jocn.2012.01.029 · DOI
  70. Ziganshina, 2010, Cerebrolysin for acute ischemic stroke, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD007026 · DOI
  71. Álvarez, 2003, Positive effects of Cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study, International Clinical Psychopharmacology, 18, 271, 10.1097/00004850-200309000-00003 · doi:10.1097/00004850-200309000-00003
  72. Álvarez, 2006, A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease, European Journal of Neurology, 13, 43, 10.1111/j.1468-1331.2006.01222.x · DOI
  73. Álvarez, 2011, Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin, European Journal of Neurology, 18, 59, 10.1111/j.1468-1331.2010.03092.x · DOI
  74. Álvarez, 2011, Cerebrolysin in Alzheimer's disease, Drugs Today (Barc), 47, 487, 10.1358/dot.2011.47.7.1656496 · DOI

Cited by

See all 90

Metadata

Authors
Chen, N., Yang, M., Guo, J., Zhou, M., Zhu, C., & He, L.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2013-01-31
Volume
2019
Issue
1
Pages
CD008900-CD008900
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1871009028
Cited by
90
References
15
FWCI
4.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.